This product is not available anymore – SEE PLACENTEX INSTEAD.
Bloomfill PDRN (Polydeoxyribonucleotide)
Meso Solution Series
• 5ml x 5 vials per box
• Usage: intradermal, transdermal (electroporation, etc.) derma roller, derma stamp, laser
FACIAL REJUVENATION – REAL RESULTS:
Pattern Hair Loss treatment protocol
12 sessions of mesotherapy is required.
Intra-perifollicular PDRN injections at weekly intervals.
After cleansing the scalp, mesotherapy injections were administered by injecting the 3-ml mixture of d-panthenol, nicotinamide, riboflavin, biotin, and zinc sulfate, all of which are approved for intra-muscular and/or intravenous injection, into the scalp us-ing an automated injector at a penetrating needle depth of 2.0-2.5 mm.
Thereafter, 2 ml of PDRN was injected into the deep dermis.
All procedures were performed without local anesthesia.
Patients were advised to refrain from applying other treatment modalities for PHL during the course of treatment and follow-up.
PDRN(Polydeoxyribonucleotide) in Patients Undergoing Skin Explants
Clinical Evaluation of the Trophic Effect of Polydeoxyribonucleotide (PDRN) in Patients Undergoing Skin Explants. (A Pilot Study)
P. Rubegni, G. De Aloe, C. Mazzatenta, M. Fimiani, Dermatological Clinic, University of Siena, Siena, Italy; L. Cattarini,
Mastelli S.r.l. – Sanremo (Im), Italy
Disclosures Curr Med Res Opin. 2001;17(2)
Summary and Introduction
Objective: The purpose of this double-blind, randomised, placebo-controlled study was to assess the
effects of intramuscular and subcutaneous PDRN in favouring the wound-healing process in donor sites
Methods: 26 adult patients of both sexes (15 males and 11 females; mean age: 68.2 ± 16.1 years) subjected
to skin explants due to plastic surgery were eligible to participate in this double-blind, placebo-controlled
study. Patients were randomly allocated into the PDRN group (14 subjects) or the placebo group (12
subjects). PDRN (5625 mg/vial) or placebo were administered by the intramuscular route once daily,
associated with a subcutaneous administration of the same dosage form (2 vials every 3 days) for 10
The primary end point for efficacy was the evolution of wound healing in donor sites, which was
evaluated measuring wound surface area and then calculating percentage re-epithelialisation. Secondary
end points were local subjective symptoms, such as pain and itching, and objective signs such as
perilesional erythema and blisters. Signs and symptoms were quantified through an analogue scale.
Results: At day 7 of the treatment period, the difference in percentage of re-epithelialisation was
statistically significant (p < 0.008) in favour of the PDRN group. At the end of the observational period,
between-group comparison demonstrated that patients treated with PDRN had a more prompt trophic
No adverse events were reported during the trial.
03 PDRN(Polydeoxyribonucleotide) in Patients Undergoing Skin Explants
Clinical Evaluation of the Trophic Effect of Polydeoxyribonucleotide (PDRN) in
Patients Undergoing Skin Explants. A Pilot Study
Conclusions: The findings of our study demonstrated that PDRN is able to modify positively the repair
processes in donor sites of autologous skin grafts. This could improve the clinical outcome and decrease
the need for additional therapies or hospital stay.
Polydeoxyribonucleotide (PDRN)* is the active principle of a drug used in cell regeneration and in wound
healing. PDRN is a fraction of low molecular weight DNA formed by polymers of deoxyribonucleotides
with chain lengths ranging between 50 and 2000 base pairs. The drug is obtained by purifying procedures
ensuring a very high percentage (up to 95%) of PDRN without active proteins or peptides because of the
purification and sterilisation methods.
This compound was used as a tissue repair-stimulating agent in a number of human diseases, such as
ulcers and burns.
In vitro, PDRN was shown to enhance the growth rate of human fibroblasts in primary cultures at
therapeutic concentrations (20-100 μg/ml)[2,3,4]. The effect on cell proliferation enhancement appears to be
mediated, at least in part, by the activation of purinergic receptors of the A2
subtype[4,5,6,7] and the
activation salvage pathway[8,9,10]. PDRN might act as a pro-drug, providing cells with effective amounts of
mitogenic deoxyribonucleotides, deoxyribonucleosides and bases
Several reports have shown the stimulant effects of nucleosides and nucleotides on proliferation of a wide
range of cell types and the cicatrizant action of A2
From a clinical standpoint, the drug is approved in Italy for both parenteral and topical use. Main targets
for its therapeutic actions are lower limb post-phlebitic ulcers, burns and other conditions needing an
activation of wound-healing processes, including depressed scars in patients suffering from acne[11,12,13]
The purpose of this double-blind, randomised, placebo-controlled pilot study was to assess the effects of
parenteral and perilesional PDRN in favouring the re-epithelialisation process in patients after a skin
04 PDRN(Polydeoxyribonucleotide) in improves wound healing
Polydeoxyribonucleotide improves wound healing of fractional laser resurfacing in rat
Background: Polydeoxyribonucleotide (PDRN) is an active compound that can promote wound healing.
PDRN stimulates wound healing by enhancing angiogenesis and increasing fibroblast growth rates. Laser
skin resurfacing is a popular cosmetic procedure for skin rejuvenation. Despite excellent improvement of
photo-damaged skin and acne scarring, it is accompanied with drawbacks, such as prolonged erythema
Objective: This study was designed to assess the effect of PDRN on wounds induced by fractional laser
Methods: Twelve male rats aged 8 weeks were randomly assigned to the PDRN treatment group and the
control group. Wounds were induced using a fractional ablative CO2
laser. The treatment group received
daily injections of PDRN and the control group received injections of the vehicle. Wound healing assessed
by clinical features and histopathologic findings.
Results: The process of wound healing was faster in the treatment group than in the control group. In the
histopathological examination, the granulation tissue thickness score of the treatment group was
significantly higher than that of the control group. Results of immunohistochemical staining showed a
marked increase of VEGF-positive cells and PECAM-1/CD31-positive microvessels in the treatment group.
Conclusion: PDRN may be a beneficial option to promote wound healing after laser treatment.
PDRN(Polydeoxyribonucleotide) in Tissue Repair Stimulating Agent
Tissue Repair Stimulating Agent with Nucleic Acid
PDRN(Polydeoxyribonucleotide), containing deoxyribonucleotide polymers where 50 to 2,000 base pairs are
combined in a chain, is know to accelerate cell proliferation by activating AW suptype purinergic receptor and
salvage pathway. PDRN was first approved for clinical use in Italy as a tissue repair stimulating agent. In Korea, It
was indicated for tissue repair and treatment of wound in skin graft in 2008 by KFDA. Its wound healing effect is
inevitably accompanied by formation and improvement of a scar. PDRN can also be applied to different clinical
indications as it increases blood supply by stimulating vascular endothelial growth factor(VEGF).
MediSobizaNews in Korea published an article titled ‘PDRN injection : Immedicate effect on the treatment of
various conditions, including alopecia, without side effects’ on September 22, 2011.
This article discusses the following : In place of platelet rich plasma(PRP) injection that has been used for the
treatment of degenerative arthiritis, bursitis, tendon rupture, alopecia, acne, scar and wound,
polydeoxyribonucleotide(PDRN) injection is gainning traction as an immediate therapy without infection or side
effects. PRP injection is commonly used for the treatment of degenerative arthrits, bursitis, tendon rupture and
frozen shoulder with 3~4 times superior efficacy. However, blood collection and processing is quite cumbersome,
the effect may vary depending on the skill of the technician, yield of the processing kit and the patient’s blood
condition. Moreover, there is a risk of infection during the processing. On the contrary, PDRN is injectable without
the process of blood collection and concentration and is free from the risks of infection and side effects. It is
convenient enough to be dubbed a ready-made PRP. It also allows injection under the real-time guidance of
arthroscopy or ultrasound image as in existing PRP/Prolotherapy. PDRN is introduced as a fundamental treatment
for adhesive capsulites by relieving the adhesion while simultaneoulsy reducing the inflammation and
regenerating the damaged tissue.
When applied to alopecia, PDRN improves blood circulation to the scalp and induces new hair growth in about
4~6 weeks, making it a new therapy for follicular cell regeneration, capillary neoformation and scalp tissue
regeneration. PDRN in the course of hair transplantation also markedly improves the survival rate of transplanted
hair and postoperative edema. For skin resurfacing, PDRN facilites the regeneration and grwoth of fibroblasts and
improves blood supply to the skin, which are helpful for maintaining skin elasticity